))
Episode 49: Jeffrey Bacha - Chairman, Rakovina Therapeutics
Manage episode 390452725 series 3526490
Treść dostarczona przez Vial. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Vial lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.
Join Jeffrey Bacha, a pioneer in the fight against cancer and the creative force behind Rakovina Therapeutics. For 25 years, Jeffrey has been reshaping the industry landscape, and today, he gives us a peek into his world of innovation. We venture into Rakovina's research and development of oncology drugs. exploring their groundbreaking technique combining PARP and HDAC inhibitors into a single molecule, a game-changer in enhancing synergy and reducing toxicity.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Rozdziały
1. Episode 49: Jeffrey Bacha - Chairman, Rakovina Therapeutics (00:00:00)
2. Redefining Cancer Treatment (00:00:07)
3. Advancements in Oncology Drug Development (00:12:09)
62 odcinków
Udostępnij
